ACRX

AcelRX Pharmaceuticals Stock Price

1.375
0.065 (4.96%)
Upgrade to Real-Time
Regular Market
1.375
Best deals to access real time data!
Big Cap Pro
Monthly Subscription
for only
$52.04
Small Cap Pro
Monthly Subscription
for only
$49.05
DDE w/Realtime (Monthly)
Monthly Subscription
for only
$34.10
VAT not included
Company Name Stock Ticker Symbol Market Type
AcelRX Pharmaceuticals Inc ACRX NASDAQ Common Stock
  Price Change Change Percent Stock Price Last Traded
0.065 4.96% 1.375 11:02:30
Open Price Low Price High Price Close Price Prev Close
1.31 1.31 1.40 1.31
Bid Price Ask Price Spread News
1.37 1.38 0.01 - -
Trades Volume VWAP Dollar Volume Avg Volume 52 Week Range
1,591 613,365 $ 1.36 $ 832,715 5,961,982 0.88 - 2.94
Last Trade Time Type Quantity Stock Price Currency
11:02:34 10 $ 1.3778 USD

AcelRX Pharmaceuticals Financials

Market Cap Shares in Issue Float Revenue Profit/Loss EPS PE Ratio
$ 136.55M 99.31M 98.16M $ 2.29M $ - -0.67 -3.40
Short Interest Dividends Per Share Dividend Yield Ex-Div Date Insider B/S Insider % Owned
- $ - 0.00% - -

more financials information »

AcelRX Pharmaceuticals News

Loading Messages....

{{bbMessage.M_Alias}} {{bbMessage.MSG_Date}} {{bbMessage.HowLongAgo}} {{bbMessage.MSG_ID}} {{bbMessage.MSG_Subject}}

Loading Messages....


No posts yet, be the first! No {{symbol}} Message Board. Create One! See More Posts on {{symbol}} Message Board See More Message Board Posts

Historical ACRX Price Data

Period Open High Low VWAP Avg. Daily Vol Change %
1 Week1.581.581.261.402,084,495-0.205-12.97%
1 Month1.821.9811.261.632,211,404-0.445-24.45%
3 Months1.962.941.262.124,898,205-0.585-29.85%
6 Months1.992.941.1552.013,828,321-0.615-30.9%
1 Year1.312.940.881.862,566,1700.0654.96%
3 Years2.405.050.70142.481,882,175-1.03-42.71%
5 Years3.585.750.70142.571,381,989-2.21-61.59%

AcelRX Pharmaceuticals Description

AcelRx Pharmaceuticals Inc is a specialty pharmaceutical company focused on the development and commercialization of therapies for use in medically supervised settings. The company has one approved product in the U.S., DSUVIA (sufentanil sublingual tablet) known as DZUVEO in Europe indicated for the management of acute pain, severe enough to require an opioid analgesic for adult patients and one product candidate, Zalviso (sufentanil sublingual tablet system) SST system being developed as an innovatively designed patient-controlled analgesia (PCA) system for the reduction of moderate-to-severe acute pain in medically supervised settings.


Your Recent History
NASDAQ
ACRX
AcelRX Pha..
Register now to watch these stocks streaming on the ADVFN Monitor.

Monitor lets you view up to 110 of your favourite stocks at once and is completely free to use.